Book Cover
Home  |   Healthcare   |  Lutetium-177 (Lu-177) Market

Lutetium-177 (Lu-177) Market Size, Share, Growth, and Industry Analysis, By Type (General Lutetium-177, High Specific Activity Lutetium-177), By Application (Nuclear Therapy, Diagnosis, Others), Regional Insights and Forecast to 2035

Trust Icon
1000+
GLOBAL LEADERS TRUST US

Lutetium-177 (Lu-177) Market Overview

The global Lutetium-177 (Lu-177) Market is projected to expand steadily from USD 595.58 Million in 2026 to USD 4631.55 Million by 2035, representing a CAGR of 25.6% during 2026-2035.

The Lutetium-177 (Lu-177) Market is expanding as targeted radionuclide therapy becomes increasingly important in precision oncology. Lutetium-177 is a therapeutic radioisotope with a physical half-life of approximately 6.65 days, allowing controlled radiation delivery through tumor-targeting molecules. Its applications include prostate cancer, neuroendocrine tumors, and investigational therapies for additional malignancies. Clinical adoption is supported by advances in radiopharmaceutical manufacturing, molecular imaging, and patient selection. High Specific Activity Lutetium-177 is increasingly important for preparing targeted treatments requiring carefully controlled isotope characteristics. Manufacturers are expanding production capabilities to improve availability and address logistical limitations. Investment in radiochemistry, isotope purification, and specialized nuclear medicine infrastructure continues to strengthen the industry's development.

The United States represents a major commercial center for Lutetium-177 radiopharmaceutical applications, supported by oncology research, treatment infrastructure, and regulatory approvals. In July 2026, an additional regulatory approval expanded the use of Novartis' Lu-177 therapy into an earlier stage of metastatic prostate cancer treatment. Clinical evidence supporting the decision demonstrated a 33% reduction in the risk of disease progression or death in the studied treatment population. This development is expected to increase demand for isotope manufacturing and radiopharmaceutical distribution. American healthcare institutions are investing in nuclear medicine facilities, specialized treatment personnel, and radiation safety systems. Growing coordination between imaging centers and oncology specialists is improving access to personalized therapeutic approaches.

Global Lutetium-177 (Lu-177) Market Size, 2035 (USD Million)

Get Comprehensive Insights into the Market’s Size and Growth Trends

downloadDownload FREE Sample

Key Findings

  • Key Market Driver: Growing adoption of targeted radioligand therapy is accelerating market expansion, with clinical studies demonstrating a 33% reduction in the risk of disease progression or death among eligible prostate cancer patients.
  • Major Market Restraint: Limited isotope production capacity and complex radioactive material distribution restrict treatment availability, with approximately 32% of nuclear medicine providers reporting supply-related scheduling difficulties.
  • Emerging Trends: Increasing demand for advanced radiopharmaceutical manufacturing and high-purity isotopes is supporting market innovation, with High Specific Activity Lutetium-177 accounting for approximately 55% of the supplied product classification.
  • Regional Leadership: North America holds approximately 81% share in the broader market assessment cited in the report, supported by established oncology infrastructure, advanced nuclear medicine facilities, and expanding radioligand treatment applications.
  • Competitive Landscape: Novartis (AAA) accounts for approximately 23% of global clinical Lutetium-177 usage in the supplied assessment, supported by approved radioligand therapies, advanced oncology research, and expanding manufacturing capabilities.
  • Market Segmentation: Nuclear Therapy dominates the application segmentation with approximately 68% share, driven by growing use of targeted radiopharmaceuticals for prostate cancer, neuroendocrine tumors, and precision oncology treatments.
  • Recent Development: In July 2026, Novartis expanded its approved Lutetium-177 prostate cancer treatment indications, supported by clinical findings demonstrating a 33% reduction in disease progression or death risk.

The Lutetium-177 (Lu-177) Market is experiencing significant innovation in isotope production, targeted radiopharmaceuticals, and personalized cancer treatment. Manufacturers increasingly emphasize non-carrier-added production processes designed to provide high specific activity and controlled chemical characteristics. High Specific Activity Lutetium-177 accounts for approximately 55% of the previously supplied product classification, reflecting growing demand for advanced radiopharmaceutical manufacturing. Research programs are exploring improved tumor-binding molecules and optimized treatment delivery systems. Molecular imaging is also becoming increasingly important for selecting appropriate patients and monitoring therapeutic responses. These advances are encouraging closer integration between radiopharmaceutical manufacturers, oncology specialists, and nuclear medicine institutions. Continued investment in advanced separation technology is expected to support greater consistency in commercial isotope availability.

Another important trend involves expanding clinical applications through new treatment indications and advanced radioligand development. Clinical results supporting expanded prostate cancer treatment demonstrated a 33% reduction in the risk of disease progression or death among the studied patients. Manufacturers are increasingly investigating targeted therapies for additional tumor characteristics and treatment stages. Radiopharmaceutical development programs emphasize improved patient selection, controlled radiation exposure, and dependable isotope supply. Clinical research is also exploring combinations with established oncology treatments. These developments are encouraging investment in specialized manufacturing facilities and distribution systems capable of supplying radioactive products within strict delivery schedules.

Lutetium-177 (Lu-177) Market Dynamics

Driver

"Growing adoption of targeted radioligand therapy in oncology."

Increasing clinical adoption of targeted radionuclide therapy is a major growth driver for the Lutetium-177 Market. A pivotal clinical study supporting expanded prostate cancer treatment demonstrated a 33% reduction in progression or death risk, reinforcing interest in therapeutic radiopharmaceuticals. Lutetium-177 delivers beta radiation through molecules designed to recognize specific tumor-associated targets. This approach enables treatment of selected cancers while requiring careful management of radiation exposure and patient eligibility. Increasing clinical evidence is encouraging healthcare organizations to invest in nuclear medicine services. Manufacturers are responding by expanding isotope production and strengthening distribution capabilities to support growing treatment demand.

Expansion of specialized oncology treatment infrastructure is also supporting market development. The reference industry assessment identifies more than 740 hospitals and specialized centers involved in Lu-177 therapy worldwide, demonstrating a substantial clinical delivery network. Treatment requires coordinated preparation, radiation protection, patient monitoring, and radioactive waste management. Healthcare institutions are increasingly developing multidisciplinary teams combining nuclear medicine, oncology, radiopharmacy, and medical physics expertise. Improvements in patient screening and treatment planning are encouraging broader use of approved radiopharmaceutical products. Reliable isotope availability remains essential as additional facilities introduce targeted radiation treatment services.

Restraint

"Restricted isotope availability and specialized distribution requirements."

Limited production capacity remains an important restraint in the Lutetium-177 Market. Approximately 32% of nuclear medicine providers in the reference industry assessment reported supply-related treatment scheduling difficulties. Manufacturing requires specialized irradiation or isotope production capabilities, followed by controlled chemical processing and quality verification. Production interruptions can affect multiple treatment facilities because radioactive materials must be delivered within defined timeframes. Manufacturers depend on reliable access to enriched starting materials, processing infrastructure, and authorized transportation services. Healthcare providers may experience scheduling difficulties when supply does not match patient demand. These constraints encourage investment in additional isotope production locations and resilient distribution arrangements.

Radioactive decay creates further logistical restrictions because Lutetium-177 has a physical half-life of approximately 6.65 days. Material activity decreases during storage and transportation, making accurate production scheduling essential. Manufacturers must coordinate irradiation, purification, quality testing, packaging, and delivery before substantial activity is lost. International shipments may require specialized documentation and compliance with radioactive material transportation regulations. Hospitals must also maintain suitable storage and dispensing arrangements. Distribution disruptions can affect treatment schedules and increase operational complexity. Manufacturers are therefore developing regional supply networks and improved logistics systems to strengthen reliability.

Opportunity

"Expanding oncology research and high-purity isotope manufacturing."

Development of additional targeted radiopharmaceuticals creates opportunities for Lutetium-177 producers. The reference industry assessment identifies more than 145 clinical investigations exploring Lu-177-based compounds and treatment approaches. Research programs evaluate tumor-associated targets and specialized molecules intended to improve treatment selectivity. High Specific Activity Lutetium-177 supports radiolabeling applications requiring controlled quantities of nonradioactive material. Manufacturers are investing in purification technology, specialized production capabilities, and research partnerships. Expansion of clinical research could increase demand for reliable isotope supply as promising treatments advance through development and regulatory evaluation.

Regional manufacturing expansion provides additional opportunities, particularly in markets developing domestic radiopharmaceutical capabilities. SHINE Technologies established a distribution partnership in March 2026 involving a 28,000-square-meter facility in China. The arrangement supports access to non-carrier-added Lu-177 and associated radiopharmaceutical processing services. Similar supply relationships may help manufacturers reach new treatment centers and research organizations. Investment in local distribution, radiolabeling, and quality-control infrastructure can improve access to specialized products. Continued international collaboration is expected to encourage technology transfer and expansion of nuclear medicine capabilities.

Challenge

"Maintaining isotope quality and reliable clinical delivery."

Maintaining consistent isotope characteristics presents a significant technical challenge for manufacturers. Lutetium-177 can lose approximately 50% of its radioactive activity during storage and distribution, requiring tightly controlled production and testing procedures. Radiopharmaceutical manufacturers must evaluate chemical impurities, radioactive contaminants, specific activity, and suitability for subsequent labeling. Variations in material characteristics can influence preparation processes and product acceptance. Specialized analytical equipment and trained radiochemistry personnel are necessary for quality assurance. Manufacturers also require validated production systems capable of delivering consistent batches under applicable regulatory requirements.

Clinical infrastructure and workforce limitations create additional implementation challenges. Lutetium-177 can lose approximately 75% of its initial radioactive activity during extended storage, highlighting the importance of timely transportation and treatment scheduling. Treatment centers must maintain shielded facilities, calibrated equipment, authorized personnel, and appropriate procedures for radioactive material management. Coordination between manufacturing schedules and patient appointments is essential to minimize activity losses during distribution. Expanding treatment availability requires investment beyond isotope production alone. Healthcare institutions must develop dependable operational processes while maintaining safety, regulatory compliance, and consistent patient care.

Lutetium-177 (Lu-177) Market Segmentation Analysis

Global Lutetium-177 (Lu-177) Market Size, 2035

Get Comprehensive Insights on the Market Segmentation in this Report

download Download FREE Sample

By Types

General Lutetium-177: General Lutetium-177 represents approximately 45% of the working product classification, encompassing isotope material supplied through established production pathways. Direct neutron irradiation of Lutetium-176 can produce carrier-added Lu-177 suitable for selected radiopharmaceutical and research applications. The material's specific activity and impurity profile depend on production conditions and subsequent processing. Manufacturers use established irradiation and quality-control procedures to maintain consistent product specifications. Demand is supported by research institutions and pharmaceutical developers evaluating isotope compatibility for different labeling requirements. Commercial suitability depends on the target molecule, intended clinical application, and regulatory specifications.

General Lutetium-177 remains important where production flexibility and established reactor infrastructure support reliable commercial availability. Its physical half-life of approximately 6.65 days provides a practical treatment and distribution window, although radioactive decay requires careful scheduling. Manufacturers are improving irradiation efficiency, radiochemical processing, and batch documentation to support dependable product delivery. Research organizations continue evaluating carrier-added materials for applications where specific activity requirements permit their use. Additional investment in reactor access and specialized handling capabilities may strengthen supply continuity. Competition increasingly depends on material consistency, quality verification, and dependable transportation rather than production capability alone.

High Specific Activity Lutetium-177: High Specific Activity Lutetium-177 accounts for approximately 55% of the reported clinical product usage classification, making it the leading supplied material category. Production commonly involves irradiation of enriched Ytterbium-176 followed by specialized chemical separation. Non-carrier-added material offers high specific activity because it contains minimal stable lutetium carrier. This characteristic is important when radiolabeling molecules with limited binding capacity or strict formulation requirements. Manufacturers emphasize radionuclidic purity, chemical consistency, and dependable supply. Demand is supported by targeted cancer therapies and experimental radiopharmaceutical programs requiring precisely characterized radioactive starting materials.

High Specific Activity Lutetium-177 is gaining commercial importance as manufacturers expand advanced radiopharmaceutical development. Selected non-carrier-added products provide radionuclidic purity of at least 99.9%, demonstrating the technical requirements associated with premium isotope production. Facilities require specialized separation systems, validated analytical methods, and controlled manufacturing environments. Continued clinical development is encouraging investment in additional production capacity and supply partnerships. Pharmaceutical companies value predictable material characteristics because radiolabeling efficiency and product consistency influence manufacturing operations. Advanced isotope purification and improved production reliability are expected to strengthen demand for this category.

By Applications

Nuclear Therapy: Nuclear Therapy dominates the supplied application classification with approximately 68% of reported Lutetium-177 usage. The segment primarily involves targeted treatment of selected cancers through radiopharmaceutical compounds designed to accumulate in tumor-associated tissues. Approved applications include certain prostate cancer and neuroendocrine tumor conditions. Treatment protocols require appropriate patient selection, radiation safety management, and multidisciplinary clinical coordination. Expanding clinical evidence supports continued interest in targeted radionuclide treatment. Healthcare providers are increasingly investing in specialized nuclear medicine services and radiopharmacy infrastructure. Commercial demand depends on approved treatment indications, isotope availability, and the capacity of authorized centers to administer therapies.

Nuclear Therapy demand is strengthening as treatment options expand into additional eligible patient populations. A 2026 clinical study supporting expanded prostate cancer use demonstrated a 33% reduction in progression or death risk. This finding illustrates the clinical relevance of appropriately selected radioligand therapy. Manufacturers are improving isotope supply, dose preparation, and distribution arrangements to support increasing treatment requirements. Healthcare institutions are also expanding imaging coordination and patient monitoring capabilities. Continued regulatory review of investigational radiopharmaceuticals could create additional commercial opportunities, although future approvals depend on demonstrated safety and clinical effectiveness.

Diagnosis: Diagnosis represents approximately 18% of the reference market's application classification, reflecting imaging-related uses and supporting clinical investigation. Lutetium-177 itself is predominantly therapeutic, although its gamma emissions can support selected post-treatment imaging and dosimetry procedures. Patient selection before treatment commonly relies on other diagnostic radioisotopes rather than Lu-177 alone. Diagnostic workflows help clinicians evaluate target expression, treatment distribution, and organ exposure. Advances in hybrid imaging and radiation dosimetry are supporting more individualized treatment planning. Demand is influenced by the availability of suitable imaging equipment, trained personnel, and established clinical protocols.

Diagnostic development increasingly emphasizes better coordination between molecular imaging and therapeutic administration. Lutetium-177 emits gamma photons suitable for selected imaging measurements, including a prominent emission near 208 kiloelectronvolts. These characteristics can assist post-therapy imaging and absorbed-dose evaluation under appropriate clinical conditions. Imaging specialists use such information to understand radiopharmaceutical distribution and support treatment assessment. Continued improvements in reconstruction methods and quantitative imaging may strengthen clinical research capabilities. However, diagnostic demand must be distinguished from the larger commercial market for therapeutic Lu-177 preparations and associated patient-selection imaging technologies.

Others: Others accounts for approximately 14% of the reference market's application classification, covering research, experimental radiochemistry, and specialized development activities outside established therapeutic and diagnostic uses. Universities, research organizations, and pharmaceutical developers use Lutetium-177 in controlled investigations involving molecular targeting, radiolabeling chemistry, and biodistribution. These activities contribute to the development of future radiopharmaceutical products. Demand is influenced by research funding, isotope availability, and the progress of experimental treatment programs. Manufacturers providing suitable research-grade materials can support early-stage development while maintaining the applicable handling and quality requirements.

Research applications increasingly focus on evaluating new targeting molecules and improving radiochemical preparation procedures. The reference industry assessment identifies more than 90 universities and research laboratories undertaking Lu-177-related investigations. Experimental work includes radiolabeling optimization, stability assessment, and investigations of radiation distribution within biological systems. These programs help identify promising candidates before larger clinical development investments. Specialized isotope suppliers support research through controlled material specifications and dependable delivery arrangements. Continued scientific collaboration is expected to increase demand for carefully characterized materials and advanced laboratory processing capabilities.

Lutetium-177 (Lu-177) Market Regional Outlook

Global Lutetium-177 (Lu-177) Market Share, by Type 2035

Get Comprehensive Insights into the Market’s Size and Growth Trends

download Download FREE Sample

North America

North America is a leading commercial market for Lutetium-177 radiopharmaceutical therapy, supported by established oncology infrastructure and expanding treatment indications. One broader market assessment assigns North America approximately 81% share, although this reflects a different market scope from isotope production volume. The United States represents the principal regional treatment center, supported by advanced cancer care facilities and active radiopharmaceutical development. Demand is increasing through expanded treatment eligibility and investment in specialized nuclear medicine infrastructure. Canada contributes through clinical research and authorized treatment facilities. Regional expansion depends on dependable isotope supply, healthcare reimbursement, and trained clinical personnel.

Manufacturing investment is strengthening North America's role in radiopharmaceutical supply. Novartis reported 5 United States radioligand therapy manufacturing facilities operational or under construction in July 2026. Domestic production capacity can improve delivery coordination and reduce dependence on long international transportation routes. SHINE Technologies is also developing commercial isotope capabilities within the United States. These activities support increased clinical availability and specialized research programs. Continued investment in quality-controlled manufacturing, regional distribution, and treatment facilities is expected to reinforce the region's importance in the global market.

Europe

Europe remains an important production center for Lutetium-177, accounting for approximately 48% of global isotope production capacity according to the reference industry assessment. Germany, the Netherlands, France, Italy, and other European countries contribute through nuclear research infrastructure and radiopharmaceutical manufacturing. Regional companies have established specialized irradiation, purification, and isotope distribution capabilities. Europe also maintains a substantial network of oncology and nuclear medicine facilities using targeted radiopharmaceuticals. Demand is supported by clinical research, treatment approvals, and specialized manufacturing expertise. Production capacity should not be confused with regional consumption share because isotope shipments frequently cross international borders.

European suppliers are increasingly developing radiopharmaceutical manufacturing partnerships and advanced isotope processing capabilities. Eckert Ziegler announced a collaboration involving 2 therapeutic radionuclides in February 2026, including Lutetium-177 for investigational targeted treatment development. Such partnerships support research organizations requiring specialized radiolabeling and manufacturing services. Regional innovation also emphasizes clinical dosimetry, radioactive material quality assurance, and efficient distribution. Established regulatory systems provide a framework for controlled manufacturing and treatment delivery. Continued investment in specialized facilities is expected to support Europe's importance within the international isotope supply network.

Asia-Pacific

Asia-Pacific accounts for approximately 19% of Lutetium-177 usage in the reference market assessment, supported by expanding nuclear medicine services and growing oncology research. China, Japan, India, and South Korea represent important markets for advanced radiopharmaceutical development. Healthcare institutions are investing in molecular imaging, targeted therapy infrastructure, and specialized clinical capabilities. Demand is influenced by cancer treatment requirements and the availability of trained nuclear medicine professionals. Regional manufacturers are also investigating opportunities to improve domestic isotope availability. Commercial development depends on regulatory approvals, healthcare funding, and dependable international supply relationships.

Manufacturing and distribution partnerships are creating opportunities for expanding regional access. SHINE Technologies established a distribution arrangement in March 2026 involving a 28,000-square-meter radiopharmaceutical facility in China. The partnership supports supply of non-carrier-added Lutetium-177 to pharmaceutical developers and healthcare organizations. Local processing capabilities can improve coordination between isotope suppliers and radiopharmaceutical manufacturers. Continued investment in quality control, specialized distribution, and clinical research is expected to support regional demand. Expanding treatment infrastructure may further improve access to approved targeted radionuclide therapies.

Middle East and Africa

The Middle East and Africa represents approximately 4% of reported Lutetium-177 usage in the reference industry assessment. Regional demand originates from specialized oncology facilities, nuclear medicine institutions, and developing radiopharmaceutical services. Saudi Arabia, the United Arab Emirates, South Africa, and Egypt are investing in healthcare infrastructure and advanced treatment capabilities. Availability remains influenced by international isotope procurement, regulatory requirements, and specialized clinical expertise. Expansion requires dependable supply chains and facilities capable of safely receiving and administering radioactive medicines. Partnerships with established manufacturers can help improve regional access to approved treatments.

Regional healthcare organizations increasingly evaluate advanced cancer treatment options alongside investment in nuclear medicine infrastructure. Procurement specifications can require isotope deliveries within 1 day of a defined calibration date, demonstrating the importance of precise shipment coordination. Clinical centers must maintain suitable radiation protection, storage, and patient monitoring capabilities. Expanding professional training and reliable distribution arrangements can strengthen treatment availability. Continued healthcare investment is expected to encourage selective growth, particularly where established oncology facilities can integrate radioligand therapy into existing services.

Rest of the World

The Rest of the World includes additional markets outside the principal regional groups, particularly countries with developing nuclear medicine infrastructure. A separately verified percentage share for this residual classification is unavailable, while Lutetium-177 maintains a physical half-life of approximately 6.65 days that influences supply arrangements in distant markets. Specialized oncology centers depend on reliable international procurement and suitable regulatory authorization. Demand is associated with targeted cancer therapy, clinical research, and expanding access to radiopharmaceutical services. Commercial development requires dependable medical isotope distribution and qualified treatment personnel.

Healthcare providers in emerging markets increasingly evaluate international partnerships for advanced radiopharmaceutical supply. A treatment pathway may involve 4 to 6 administration cycles, depending on the approved product, indication, and individual clinical circumstances. Scheduling requires coordination between isotope availability, patient readiness, and authorized treatment facilities. Investment in radiopharmacy capabilities and specialized clinical training may improve regional access. Continued expansion is expected to remain gradual as healthcare systems develop appropriate facilities and establish dependable supply relationships.

List of Top Lutetium-177 (Lu-177) Market Companies

  • Novartis (AAA)
  • Eczacıbaşı Monrol
  • ITM Isotope
  • SHINE Technologies
  • Eckert Ziegler

Top 2 Companies with Highest Market Share

  • Novartis (AAA): Novartis is associated with approximately 23% of global clinical Lutetium-177 usage in the reference market assessment, representing the midpoint of its published share range rather than an independently audited current market share. The company maintains a leading position through established radioligand therapies, regulatory development, and specialized pharmaceutical manufacturing. Its expanded 2026 prostate cancer treatment approval strengthened commercial opportunities. Continued investment in manufacturing infrastructure and clinical research supports its role in targeted oncology treatment.
  • ITM Isotope: ITM Isotope is associated with approximately 20% of global High Specific Activity Lutetium-177 distribution in the reference assessment, representing the midpoint of its published supply-share range. The company specializes in non-carrier-added isotope production and radiopharmaceutical development. Its manufacturing capabilities support pharmaceutical companies and clinical research programs requiring reliable radioactive starting materials. The August 2026 isotope supply agreement with Akiram Therapeutics demonstrated continued expansion into investigational treatments for additional solid tumors.

Investment Analysis and Opportunities

Investment in the Lutetium-177 Market increasingly focuses on isotope manufacturing capacity, purification technology, radiopharmaceutical development, and specialized distribution infrastructure. High Specific Activity Lutetium-177 represents approximately 55% of reported clinical product usage, highlighting the importance of advanced production processes. Manufacturers are investing in non-carrier-added isotope capabilities to support pharmaceutical development and approved cancer treatments. Commercial opportunities include enriched starting material production, radiochemical separation, quality-control laboratories, and reliable transportation networks. Healthcare organizations are also expanding authorized treatment facilities and specialized radiopharmacy services. Investment decisions depend on production reliability, regulatory compliance, isotope characteristics, and the ability to coordinate supply with clinical demand.

International supply partnerships and advanced oncology research are creating additional investment opportunities. The reference industry assessment identifies more than 145 clinical investigations involving Lutetium-177-based compounds and treatment approaches. Pharmaceutical developers require dependable isotope access throughout clinical research and potential commercialization. Manufacturers offering controlled specifications and reliable delivery schedules may strengthen their position within the radiopharmaceutical supply chain. Regional manufacturing development can also reduce transportation dependencies and improve operational flexibility. Continued investment in automated processing, specialized personnel, and clinical infrastructure is expected to support broader adoption of targeted radionuclide treatment.

New Product Development

New product development in the Lutetium-177 Market emphasizes improved isotope purity, specific activity, manufacturing consistency, and targeted treatment performance. SHINE Technologies is advancing its Ilumira product to support growing demand for non-carrier-added Lutetium-177 in radiopharmaceutical manufacturing. The company has established partnerships to expand isotope distribution and improve access to specialized radioactive materials. Manufacturers are developing advanced purification technologies and analytical procedures to support radiopharmaceutical preparation. Research organizations are investigating tumor-targeting molecules designed for controlled radiation delivery. Continued investment in specialized isotope production is expected to strengthen supply reliability and support additional clinical development programs.

Clinical innovation is expanding opportunities for radiopharmaceutical manufacturers and research organizations. In July 2026, Novartis received regulatory approval for an additional prostate cancer treatment indication following clinical results demonstrating a 33% reduction in the risk of disease progression or death. This development highlights the growing clinical importance of targeted radioligand therapy. Manufacturers are exploring advanced radiolabeling methods, specialized delivery molecules, and improved dosimetry technologies. Continued collaboration between isotope suppliers, pharmaceutical developers, and nuclear medicine institutions is expected to improve treatment precision, manufacturing reliability, and access to advanced oncology therapies.

Five Recent Developments

  • February 2026 – Eckert Ziegler Announces Targeted Radiopharmaceutical Development Partnership:Eckert Ziegler entered a partnership with Molecular Partners to support development and future manufacturing of Radio-DARPin therapeutics involving 2 therapeutic radionuclides, including Lutetium-177. The collaboration strengthens capabilities for investigational targeted cancer treatments.
  • March 2026 – SHINE Technologies Expands Lutetium Distribution Across China:SHINE Technologies established an exclusive distribution agreement with C-Ray Therapeutics for non-carrier-added Lutetium-177 in mainland China, subject to existing arrangements. The partnership incorporates a 28,000-square-meter facility supporting radiopharmaceutical processing and quality control.
  • May 2026 – SHINE Technologies Secures European Isotope Marketing Authorization:SHINE Technologies obtained European marketing authorization for Ilumira, its non-carrier-added Lutetium-177 product with specified radionuclidic purity of at least 99.9%. The authorization expanded the company's ability to supply isotope material within the European market.
  • July 2026 – Novartis Expands Approved Prostate Cancer Treatment Indications:Novartis received additional United States regulatory approval for its Lutetium-177 radioligand therapy in an earlier metastatic prostate cancer setting. Supporting clinical results demonstrated a 33% reduction in progression or death risk compared with the control treatment approach.
  • August 2026 – ITM Isotope Expands Investigational Radiopharmaceutical Supply Partnerships:ITM Isotope announced a non-carrier-added Lutetium-177 supply agreement with Akiram Therapeutics to support development of AKIR001. The candidate entered Phase 1 clinical investigation for selected advanced solid tumors expressing the targeted cancer marker.

Future Outlook

The Lutetium-177 Market is expected to experience sustained development as targeted radionuclide therapies become increasingly integrated into specialized oncology care. Its physical half-life of approximately 6.65 days will remain an important consideration in manufacturing, transportation, and treatment scheduling. Demand is expected to benefit from additional clinical research, expanding treatment indications, and improvements in isotope production technology. High Specific Activity Lutetium-177 will remain important for radiopharmaceutical compounds requiring carefully controlled material characteristics. Manufacturers are expected to prioritize production reliability, advanced purification, and dependable international distribution. Healthcare institutions will continue investing in specialized treatment infrastructure and multidisciplinary clinical expertise.

Future competitive conditions will be influenced by isotope availability, regulatory approvals, clinical effectiveness, and manufacturing consistency. The reference industry assessment identifies more than 145 clinical investigations involving Lutetium-177-based compounds, illustrating continuing research interest. Manufacturers and pharmaceutical developers are expected to strengthen partnerships supporting investigational therapies and commercial treatment supply. Expansion into additional oncology applications will depend on successful clinical trials and regulatory decisions. Improved radiochemistry, specialized manufacturing infrastructure, and reliable logistics are expected to support broader access to approved treatments. Continued investment in targeted radiopharmaceutical development will remain central to the market's evolution through 2035.

Lutetium-177 (Lu-177) Market Report Coverage

REPORT COVERAGE DETAILS

Market Size Value In

USD 595.58 Million in 2026

Market Size Value By

USD 4631.55 Million by 2035

Growth Rate

CAGR of 25.6% from 2026-2035

Forecast Period

2026 - 2035

Base Year

2025

Historical Data Available

Yes

Regional Scope

Global

Segments Covered

By Type :

  • General Lutetium-177
  • High Specific Activity Lutetium-177

By Application :

  • Nuclear Therapy
  • Diagnosis
  • Others

To Understand the Detailed Market Report Scope & Segmentation

download Download FREE Sample

Frequently Asked Questions

The global Lutetium-177 (Lu-177) Market is expected to reach USD 4631.55 Million by 2035.

The Lutetium-177 (Lu-177) Market is expected to exhibit a CAGR of 25.6% by 2035.

Novartis (AAA), Eczacıbaşı Monrol, ITM Isotope, SHINE Technologies, Eckert Ziegler

In 2026, the Lutetium-177 (Lu-177) Market value will reach at USD 595.58 Million.

faq right

Our Clients

Captcha refresh

Trusted & Certified